[go: up one dir, main page]

PE20200607A1 - Etanercept correctamente plegado de alta pureza y excelente rendimiento - Google Patents

Etanercept correctamente plegado de alta pureza y excelente rendimiento

Info

Publication number
PE20200607A1
PE20200607A1 PE2019002512A PE2019002512A PE20200607A1 PE 20200607 A1 PE20200607 A1 PE 20200607A1 PE 2019002512 A PE2019002512 A PE 2019002512A PE 2019002512 A PE2019002512 A PE 2019002512A PE 20200607 A1 PE20200607 A1 PE 20200607A1
Authority
PE
Peru
Prior art keywords
etanercept
high purity
excellent performance
weight
protein
Prior art date
Application number
PE2019002512A
Other languages
English (en)
Inventor
Tsutomu Arakawa
Douglas Farrar
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20200607(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of PE20200607A1 publication Critical patent/PE20200607A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Referido a una mezcla de proteinas que contiene etanercept correctamente plegado en una cantidad que constituye mas que un 90 % en peso de la mezcla de proteinas que contiene etanercept; y etanercept incorrectamente plegado en una cantidad de menos que un 5 % en peso de la mezcla de proteinas; y la mezcla de proteinas tiene una cantidad combinada de etanercept correctamente e incorrectamente plegado que constituye al menos 95 % en peso de la mezcla de proteinas que contiene etanercept. Dicha mezcla es producida por un metodo de cromatografia de modo mixto. Tambien se refiere a una formulacion y una composicion farmaceuticamente aceptable que contienen dicha mezcla de proteinas que contienen etanercept.
PE2019002512A 2012-09-11 2013-09-10 Etanercept correctamente plegado de alta pureza y excelente rendimiento PE20200607A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11
PCT/US2013/058994 WO2014043103A1 (en) 2012-09-11 2013-09-10 Correctly folded etanercept in high purity and excellent yield

Publications (1)

Publication Number Publication Date
PE20200607A1 true PE20200607A1 (es) 2020-03-10

Family

ID=50233493

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019002512A PE20200607A1 (es) 2012-09-11 2013-09-10 Etanercept correctamente plegado de alta pureza y excelente rendimiento
PE2015000316A PE20150996A1 (es) 2012-09-11 2013-09-10 Etanercept correctamente plegado de alta pureza y excelente rendimiento

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2015000316A PE20150996A1 (es) 2012-09-11 2013-09-10 Etanercept correctamente plegado de alta pureza y excelente rendimiento

Country Status (33)

Country Link
US (6) US20140072560A1 (es)
EP (1) EP2895188B1 (es)
JP (3) JP2015533797A (es)
KR (2) KR102133699B1 (es)
CN (2) CN104902914B (es)
AR (1) AR092532A1 (es)
AU (2) AU2013315750B9 (es)
BR (1) BR112015005161A2 (es)
CA (1) CA2882551A1 (es)
CL (1) CL2015000572A1 (es)
CO (1) CO7400876A2 (es)
CY (1) CY1120062T1 (es)
DK (1) DK2895188T3 (es)
DO (1) DOP2015000055A (es)
EA (1) EA031324B1 (es)
EC (1) ECSP15014138A (es)
ES (1) ES2657377T3 (es)
HR (1) HRP20180182T1 (es)
HU (1) HUE036524T2 (es)
IL (2) IL237311B (es)
IN (1) IN2015KN00452A (es)
LT (1) LT2895188T (es)
MX (2) MX360044B (es)
NO (1) NO2972131T3 (es)
PE (2) PE20200607A1 (es)
PL (1) PL2895188T3 (es)
PT (1) PT2895188T (es)
RS (1) RS57013B1 (es)
SG (1) SG11201501460RA (es)
SI (1) SI2895188T1 (es)
SM (1) SMT201800163T1 (es)
TW (2) TWI609877B (es)
WO (1) WO2014043103A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
TWI595883B (zh) 2011-10-18 2017-08-21 柯赫勒斯生物科學有限公司 用木糖醇穩定化之依那西普調配物
BR112015005161A2 (pt) * 2012-09-11 2017-07-04 Coherus Biosciences Inc etanercepte corretamente dobrado em alta pureza e excelente rendimento
US10556942B2 (en) 2014-06-13 2020-02-11 Lupin Limited Process for the purification of TNFR:Fc fusion protein
EP2975050B1 (en) * 2014-07-18 2019-05-29 Sandoz Ag Quantification of misfolded TNFR2:Fc
US10988527B2 (en) 2014-12-31 2021-04-27 Lg Chem, Ltd. Method for preparing TNFR-Fc fusion protein containing target content of impurities
KR20170138426A (ko) 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
MX2018005831A (es) * 2015-11-18 2018-08-01 Merck Patent Gmbh Gradientes de ph-sal opuestos para separaciones de proteina mejoradas.
KR20180083409A (ko) * 2015-11-18 2018-07-20 메르크 파텐트 게엠베하 이온 교환 크로마토그래피에서의 개선된 단백질 분리
PL3472177T3 (pl) * 2016-06-17 2024-11-25 F. Hoffmann-La Roche Ag Oczyszczanie przeciwciał wieloswoistych
KR102446838B1 (ko) * 2016-10-21 2022-09-26 암젠 인크 약학적 제형 및 그의 제조 방법
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
JP7655610B2 (ja) * 2017-03-24 2025-04-02 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ 組換え抗体断片の精製方法
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
US20230167153A1 (en) 2020-05-01 2023-06-01 Kashiv Biosciences, Llc An improved process of purification of protein
JP2024510480A (ja) * 2021-03-16 2024-03-07 カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー 融合タンパク質の新規製剤
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
AU2022369694B2 (en) * 2021-10-19 2025-10-09 Alteogen, Inc Method for purifying fusion protein having igg fc domain

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
ATE309376T1 (de) 1990-06-28 2005-11-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
CA2123593C (en) 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2001058473A1 (en) 2000-02-10 2001-08-16 Wyeth Method of treating or inhibiting cellular injury or cell death
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
EE200300408A (et) 2001-02-23 2003-12-15 Immunex Corporation Aktiivsete valkude saagise suurendamine
PT1478394E (pt) * 2002-02-27 2008-10-08 Immunex Corp Composição estabilizada compreendendo tnfr - fc e arginina
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
US8937045B2 (en) 2003-02-28 2015-01-20 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding proteins
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
NZ545221A (en) 2003-08-01 2009-09-25 Amgen Inc Crystalline tumor necrosis factor receptor 2 polypeptides
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
US7750129B2 (en) * 2004-02-27 2010-07-06 Ge Healthcare Bio-Sciences Ab Process for the purification of antibodies
WO2005082377A1 (ja) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
CN1930281A (zh) 2004-03-05 2007-03-14 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
JP5068167B2 (ja) 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
CA2634547C (en) 2005-12-20 2016-10-11 Bristol-Myers Squibb Company Stable ctla4 formulation for subcutaneous administration
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
BRPI0709598A8 (pt) 2006-03-17 2019-01-08 Biogen Idec Inc composições de polipeptídeos estabilizados
JP2009534390A (ja) 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
EP2081553B1 (en) 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
WO2008051363A2 (en) 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
JP5401319B2 (ja) 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
EP2129401B8 (en) 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
KR20090127326A (ko) 2007-03-02 2009-12-10 와이어쓰 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
BRPI0814252B8 (pt) 2007-06-14 2021-05-25 Biogen Idec Inc composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
CA2707483A1 (en) 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
AU2009222115A1 (en) 2008-02-29 2009-09-11 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
JP5677943B2 (ja) * 2008-06-05 2015-02-25 アフィボディ・アーベーＡｆｆｉｂｏｄｙ Ａｂ ポリペプチド
WO2011015926A1 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
JP5791602B2 (ja) 2009-08-07 2015-10-07 イー・エム・デイー・ミリポア・コーポレイシヨン 試料中の１つ以上の不純物から標的タンパク質を精製するための方法
KR20180010324A (ko) 2009-08-11 2018-01-30 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
EP2490780A4 (en) * 2009-10-20 2014-04-09 Merck Sharp & Dohme USE OF A MIXED MODE CHROMATOGRAPHY FOR THE DETECTION AND PURIFICATION OF BASIC ANTIBODY PRODUCTS
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
JP6347949B2 (ja) 2010-04-26 2018-06-27 ノバルティス アーゲー 改良型細胞培養培地
RU2600847C2 (ru) * 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
EP2598167B1 (en) 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
KR20130101034A (ko) 2010-08-31 2013-09-12 프리슬랜드 브랜즈 비브이 진핵 세포를 위한 배양 배지
CN103379949B (zh) * 2010-10-11 2016-09-14 艾伯维巴哈马有限公司 蛋白纯化方法
AU2012244764B2 (en) 2011-04-20 2016-10-13 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
AU2012279205B2 (en) 2011-07-01 2017-08-31 Biogen Ma Inc. Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use
WO2013006479A2 (en) 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
WO2013009526A1 (en) * 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Method for purifying fc-fusion protein
WO2013025079A1 (en) 2011-08-17 2013-02-21 Hanwha Chemical Corporation Method for preparing active form of tnfr-fc fusion protein
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
TWI595883B (zh) * 2011-10-18 2017-08-21 柯赫勒斯生物科學有限公司 用木糖醇穩定化之依那西普調配物
WO2014011672A1 (en) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
BR112015005161A2 (pt) * 2012-09-11 2017-07-04 Coherus Biosciences Inc etanercepte corretamente dobrado em alta pureza e excelente rendimento
WO2016015163A1 (en) * 2014-07-31 2016-02-04 Mtt Innovation Incorporated Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
PL2895188T3 (pl) 2018-06-29
CA2882551A1 (en) 2014-03-20
US20190300601A1 (en) 2019-10-03
CL2015000572A1 (es) 2016-02-05
ES2657377T3 (es) 2018-03-05
TW201803593A (zh) 2018-02-01
US20190330325A1 (en) 2019-10-31
US20140072560A1 (en) 2014-03-13
AU2018247244B2 (en) 2020-05-28
IL267452A (en) 2019-08-29
KR20150056601A (ko) 2015-05-26
IL237311B (en) 2019-07-31
HRP20180182T1 (hr) 2018-04-20
SI2895188T1 (en) 2018-05-31
RS57013B1 (sr) 2018-05-31
WO2014043103A1 (en) 2014-03-20
EP2895188A4 (en) 2016-05-25
JP2015533797A (ja) 2015-11-26
US10954294B2 (en) 2021-03-23
AU2013315750A1 (en) 2015-03-05
AR092532A1 (es) 2015-04-22
HUE036524T2 (hu) 2018-07-30
AU2018247244A1 (en) 2018-11-01
CN104902914B (zh) 2019-01-01
BR112015005161A2 (pt) 2017-07-04
JP6913066B2 (ja) 2021-08-04
CN104902914A (zh) 2015-09-09
US11001627B2 (en) 2021-05-11
PT2895188T (pt) 2018-02-08
JP2021100929A (ja) 2021-07-08
PE20150996A1 (es) 2015-08-01
AU2013315750B2 (en) 2018-07-12
DOP2015000055A (es) 2015-04-30
EA031324B1 (ru) 2018-12-28
DK2895188T3 (en) 2018-02-26
SMT201800163T1 (it) 2018-05-02
CO7400876A2 (es) 2015-09-30
MX360044B (es) 2018-10-19
MX2018012749A (es) 2020-11-12
SG11201501460RA (en) 2015-04-29
AU2013315750B9 (en) 2018-11-15
TWI609877B (zh) 2018-01-01
ECSP15014138A (es) 2016-01-29
KR20200085937A (ko) 2020-07-15
CN110051823A (zh) 2019-07-26
EP2895188B1 (en) 2017-11-15
TWI716649B (zh) 2021-01-21
IL267452B (en) 2021-05-31
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (es) 2018-04-21
IN2015KN00452A (es) 2015-07-17
IL237311A0 (en) 2015-04-30
TW201425331A (zh) 2014-07-01
US20190300600A1 (en) 2019-10-03
LT2895188T (lt) 2018-04-10
EP2895188A1 (en) 2015-07-22
US10954293B2 (en) 2021-03-23
US20180037642A1 (en) 2018-02-08
EA201590542A1 (ru) 2015-07-30
US20190300602A1 (en) 2019-10-03
US10954295B2 (en) 2021-03-23
MX2015003090A (es) 2015-07-14
CY1120062T1 (el) 2018-12-12
US10947306B2 (en) 2021-03-16
KR102133699B1 (ko) 2020-07-14
JP2019038817A (ja) 2019-03-14

Similar Documents

Publication Publication Date Title
PE20200607A1 (es) Etanercept correctamente plegado de alta pureza y excelente rendimiento
AR133787A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
AR088460A1 (es) Formulaciones de etanercept estabilizadas con aminoacidos
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
EA201600305A1 (ru) Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
CA2818187C (en) Bromodomain inhibitors and uses thereof
EP4233892A3 (en) Stable anti-ifnar1 formulation
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
CL2008003480A1 (es) Compuestos derivados de amino-pirimidina, con propiedades inmunomoduladoras y que actuan a traves de tlr7; proceso para preparar los compuestos; compuestos intermediarios; composicion y combinacion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
BR112013026883A2 (pt) Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica
AU2016219738A1 (en) Designer peptide-based PCV2 vaccine
BR112012028711A2 (pt) métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit
BR112017001860A2 (pt) peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
EA201391489A1 (ru) Композиции со сниженной вязкостью
EA201291061A1 (ru) Способ получения изотопа
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
MX366051B (es) Composiciones del virus del síndrome reproductor y respiratorio de porcino y sus usos.
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
CY1118657T1 (el) 6((s)-1-{1-[5-(2-yδpoξy-aiθoξy)-πypiδin-2-yλo]-1η-πypazoλ-3-yλo}-aiθyλo)-3η-1,3-βενζοθειαζολ-2-ονη) ως ενας εξαρτωμενος απο tarp γ8 ανταγωνιστης υποδοχεα αμρα
BR112013016590A2 (pt) uso de estabilizantes de glutamina
MX366622B (es) Composicion farmaceutica estable de la proteina de fusion tnfr:fc.
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida